Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

被引：0
作者：
Fan Yang
Xiang Huang
Chunxiao Sun
Jianbin Li
Biyun Wang
Min Yan
Feng Jin
Haibo Wang
Jin Zhang
Peifen Fu
Tianyu Zeng
Jian Wang
Wei Li
Yongfei Li
Mengzhu Yang
Jun Li
Hao Wu
Ziyi Fu
Yongmei Yin
Zefei Jiang
机构：
[1] The First Affiliated Hospital of Nanjing Medical University,Department of Oncology
[2] The First Clinical College of Nanjing Medical University,Department of Breast Cancer
[3] The 307 Hospital of Chinese People’s Liberation Army,Department of Medical Oncology
[4] Fudan University Shanghai Cancer Center,Department of Breast Cancer
[5] Henan Cancer Hospital,Department of Breast Surgery
[6] the First Affiliated Hospital of China Medical University,Department of Breast Cancer Center
[7] Affiliated Hospital of Medical College Qingdao University,Department of Breast Cancer
[8] Tianjin Medical University Cancer Institute and Hospital,Department of Breast Center, The First Affiliated Hospital, College of Medicine
[9] Zhejiang University,Department of Oncology
[10] The Third Affiliated Hospital of Soochow University,Nanjing Maternal and Child Health Medical Institute
[11] Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University,Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine
[12] Nanjing Medical University,undefined
来源：
BMC Cancer | / 20卷
关键词：
Lapatinib; Trastuzumab; Resistance; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 130 条
[1]  
Siegel RL(2017)Cancer Statistics, 2017 CA Cancer J Clin 67 7-30
[2]  
Miller KD(2001)The basic biology of HER2 Ann Oncol 12 S3-S8
[3]  
Jemal A(2014)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update Arch Pathol Lab Med 138 241-256
[4]  
Rubin I(2009)The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320-368
[5]  
Yarden Y(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
[6]  
Wolff AC(2005)Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265-4274
[7]  
Hammond ME(2017)11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 389 1195-1205
[8]  
Hicks DG(2007)Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice N Engl J Med 357 39-51
[9]  
Ross JS(2012)Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer Ann Oncol 23 3007-3016
[10]  
Slodkowska EA(2011)HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Expert Rev Anticancer Ther 11 263-275
12345678910